澳大利亚11年HPV疫苗接种不良事件监测
澳大利亚2007年起实施四价HPV疫苗(4vHPV)免疫规划,2013年起纳入男性,本文分析11年上市后监测数据,重点考察强化监测期与特殊关注不良事件(AESI)。九百万剂次中报告4551例不良事件,粗报告率39.8/10万剂;晕厥在年轻青少年中报告率较高,其他AESI罕见且未见提示因果关联的异常模式,支持4vHPV安全性。
要点
- 九百万剂4vHPV中报告4551例不良事件,粗报告率39.8/10万剂。
- 12–13岁青少年晕厥报告率强化监测期29.6/10万剂,其余期7.1/10万剂。
- 过敏性休克率0.32/10万剂,与已发表数据一致;其他AESI罕见。
核心结论
- 除晕厥外,特殊关注不良事件报告罕见,分析未发现提示因果关联的异常模式。
- 大规模长期数据支持四价HPV疫苗的安全性。
研究设计与样本
- 分析2007年4月至2017年12月澳大利亚国家监管机构收到的4vHPV接种后不良事件报告。
- 2013–2014年强化监测期报告单独分析,分母来自国家HPV疫苗接种登记。
- 预设AESI采用MedDRA首选术语识别并详细分析。
主要发现
- 九百万剂4vHPV接种后识别4551例不良事件报告。
- 排除强化监测期,免疫规划队列粗报告率为39.8/10万剂。
- 12–13岁男性与女性晕厥报告率在强化监测期为29.6/10万剂,其余研究期为7.1/10万剂。
- 过敏性休克报告率为0.32/10万剂,与已发表率一致。
- 自身免疫病、体位性心动过速综合征、原发性卵巢功能不全、吉兰-巴雷综合征、复杂性区域疼痛综合征和静脉血栓栓塞等AESI报告率低。
临床怎么用
- 年轻青少年接种后晕厥报告率较高,需落实管理方案以预防晕厥相关损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia was the first country to implement a fully funded vaccination program with quadrivalent human papillomavirus vaccine (4vHPV) in 2007, including males from 2013. We examined adverse events (AE) following vaccination with 4vHPV from 11 years of post-marketing data, focusing on a period of enhanced surveillance and adverse events of special interest (AESI). METHODS: AE following 4vHPV doses administered between April 2007 and December 2017 reported to Australia's national regulator, the Therapeutic Goods Administration, were examined; reports collected during enhanced surveillance in 2013 and 2014 were analyzed separately. Age and sex-specific rates, using denominator data from the national HPV vaccination register, were determined. Pre-specified AESI were identified using Medical Dictionary for Regulatory Activities (MedDRA®) Preferred Terms and examined in detail. FINDINGS: Following nine million doses of 4vHPV vaccine administered in Australia, 4551 AE reports were identified. The crude reporting rate was 39.8 per 100 000 doses in the funded cohorts, excluding the enhanced surveillance period. The reported rate of syncope in 12 to 13-year-old males and females was 29.6 per 100 000 doses during enhanced surveillance and 7.1 per 100 000 doses during the remaining study period; rates of syncope were higher in younger compared to older adolescents. The rate of anaphylaxis (0.32 per 100 000 doses) was consistent with published rates. Other AESI including autoimmune disease, postural orthostatic tachycardia syndrome, primary ovarian insufficiency, Guillain-Barré syndrome, complex regional pain syndrome and venous thromboembolism, were reported at low rates and analysis did not reveal unexpected patterns that would suggest causal association. INTERPRETATION: AESI, apart from syncope, were reported rarely. The higher rate of syncope among younger adolescents highlights the need for management protocols to prevent syncope-related injury. Analysis of this large, longitudinal dataset in a country with high vaccine uptake, including a period of enhanced surveillance, affirms the safety profile of 4vHPV.
引用
- Phillips A, Hickie M, Totterdell J, et al. Adverse events following HPV vaccination: 11 years of surveillance in Australia. Vaccine. 2020. PMID: 32709432. doi:10.1016/j.vaccine.2020.06.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。